Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy

COVID-19

Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy

Single fraction whole lung radiotherapy

Radiation Oncology Department, ASST SpedaliCivili, Brescia

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)

Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19)

Evaluation of the feasibility of low-dose radiotherapy treatment of SARS-Cov2 pneumonia, for the purpose of the subsequent implementation of a phase II study; lenght of hospital stay will be recorded

Evaluation of the feasibility of low-dose radiotherapy treatment of SARS-Cov2 pneumonia; the number of intensive care unit admissions will be recorded

Variation of the patient's score according to the Brescia COVID-19 Respiratory Severity Scale (minimum value 0, maximum value 8; higher scores mean a worse outcome) with baseline, assessed at 3, 6 and 10 days after treatment.

Evaluation of the safety and tolerance of the low-dose radiotherapy treatment of SARS-Cov2 ( using the CTCAE 5.0 scale)

Variation of the radiological findings, assessed by chest X-ray (performed 3 and 6 days after treatment) and defined according to the Brixia scoring system (0-18 scale, with 18 meaning the worse outcome)

All Individual Participant Data that underlie results in the publication

Stefano Maria Magrini

Prof

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.

Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.

Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.

Aggressive Periodontitis

EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.

Enamel Matrix Proteins

After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.

Open Flap Debridement

Piracicaba Dental School, State University of Campinas

Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis

Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis: Randomized Clinical Trial

Enilson Antonio Sallum

Professor Enilson Antonio Sallum

University of Campinas, Brazil

Cancer Cachexia

Ruxolitinib

Division of Hematology/Oncolgy, University Clinic of Medicine, Kantonsspital Aarau AG

Division of Hematology/Oncology, Kantonsspital Olten

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Dual energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA)

Formula BMI = W / H2 (W=body weight in kilograms; H=body height in meters)

Reporting of adverse events according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Measurement of power and speed on a stair climbing test (Stair climb speed [m/sec]=[height of 12 steps(meters)]/[time (seconds) up the 12 steps]; Stair climb power [watts]=[9.8 m/sec2]*[weight (kg)]*[height of 12 steps(meters)]/[time (seconds) up the 12 steps]).

Multiplex-assays for proinflammatory cytokines

Free oxygen radical monitor (FORM) with proper kits (FORMOX with FORT and FORD analysis kits, Callegari 1930 S.P.A., Parma, Italy).

proteinase/demam

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)

Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Database tanaman obat terlengkap yang didukung oleh sains